168 related articles for article (PubMed ID: 6238805)
1. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
Gudmundsson JA; Nillius SJ; Bergquist C
Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
[TBL] [Abstract][Full Text] [Related]
2. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Gudmundsson JA; Nillius SJ; Bergquist C
Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
[TBL] [Abstract][Full Text] [Related]
3. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Brenner PF; Shoupe D; Mishell DR
Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
[TBL] [Abstract][Full Text] [Related]
4. A new superagonist of GnRH for inhibition of ovulation in women.
Nillius SJ; Gudmundsson J; Bergquist C
Ups J Med Sci; 1984; 89(2):147-50. PubMed ID: 6235657
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.
Nillius SJ
J Steroid Biochem; 1985 Nov; 23(5B):849-54. PubMed ID: 2934581
[TBL] [Abstract][Full Text] [Related]
6. Peptide contraception by inhibition of ovulation with intranasal GnRH superagonist: clinical and metabolic aspects.
Gudmundsson JA; Bergquist C; Nillius SJ
Prog Clin Biol Res; 1986; 225():337-51. PubMed ID: 2947248
[TBL] [Abstract][Full Text] [Related]
7. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
8. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.
Monroe SE; Henzl MR; Martin MC; Schriock E; Lewis V; Nerenberg C; Jaffe RB
Fertil Steril; 1985 Mar; 43(3):361-8. PubMed ID: 3156770
[TBL] [Abstract][Full Text] [Related]
9. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
Bouchard P; Wolf JP; Hajri S
Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).
Monroe SE; Blumenfeld Z; Andreyko JL; Schriock E; Henzl MR; Jaffe RB
J Clin Endocrinol Metab; 1986 Dec; 63(6):1334-41. PubMed ID: 2946710
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
13. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
14. Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception.
Gudmundsson JA; Lundkvist O; Bergquist C; Lindgren A; Nillius SJ
Fertil Steril; 1987 Jul; 48(1):52-6. PubMed ID: 2954864
[TBL] [Abstract][Full Text] [Related]
15. Dose-related changes in LH bioactivity with intranasal GnRH agonist administration.
Chiang RS; Barnes RB; Shoupe D; Lobo RA
Contraception; 1985 Oct; 32(4):347-57. PubMed ID: 2934222
[TBL] [Abstract][Full Text] [Related]
16. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).
Schriock ED; Monroe SE; Martin MC; Henzl MR; Jaffe RB
Fertil Steril; 1985 Jun; 43(6):844-50. PubMed ID: 3158549
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.
Bergquist C; Nillius SJ; Wide L
Contraception; 1979 May; 19(5):497-506. PubMed ID: 380892
[TBL] [Abstract][Full Text] [Related]
18. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
Yen SS
Fertil Steril; 1983 Mar; 39(3):257-66. PubMed ID: 6130985
[TBL] [Abstract][Full Text] [Related]
20. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
